STOCK TITAN

InspireMD Inc - NSPR STOCK NEWS

Welcome to our dedicated news page for InspireMD (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on InspireMD.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect InspireMD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of InspireMD's position in the market.

Rhea-AI Summary
InspireMD, Inc. announced that CEO Marvin Slosman will participate in three upcoming investor conferences in November. The conferences include Wolfe Research Healthcare Conference on November 15, Canaccord Genuity MedTech, Diagnostics, Digital Health & Services Forum on November 16, and Piper 35th Annual Healthcare Conference on November 29. The presentations will be available as a live webcast on the company's website with replays available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.41%
Tags
conferences
-
Rhea-AI Summary
InspireMD presents 30-day results from the C-GUARDIANS trial at the VIVA meeting. The trial evaluated the safety and efficacy of the CGuard Carotid Stent System in treating carotid artery stenosis. The primary endpoint showed a low major adverse event rate of 0.95% through 30 days post-procedure. InspireMD anticipates reporting primary endpoint results in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.21%
Tags
-
Rhea-AI Summary
InspireMD, Inc. (Nasdaq: NSPR) will report its third quarter 2023 financial results on November 6th, 2023. The company will host a conference call and webcast at 8:30 a.m. EST on the same day to review financial results and provide corporate updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.07%
Tags
conferences earnings
Rhea-AI Summary
InspireMD supports CMS's expansion of coverage for carotid artery stenting, potentially increasing market size
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
none
-
Rhea-AI Summary
InspireMD announces senior leadership additions and changes to support commercial growth initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
InspireMD to present 30-day results from C-Guardians trial at VIVA23 conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.01%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
none
InspireMD Inc

Nasdaq:NSPR

NSPR Rankings

NSPR Stock Data

54.42M
10.97M
20.14%
44.08%
0.38%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Israel
4 Menorat Hamaor St

About NSPR

inspiremd, inc. is a company based out of 800 boylston street suite 16041, boston, massachusetts, united states.